Macugen (pegaptanib) + Macugen (Pegaptanib)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proliferative Diabetic Retinopathy
Conditions
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Trial Timeline
Oct 1, 2006 → Sep 1, 2008
NCT ID
NCT00446381About Macugen (pegaptanib) + Macugen (Pegaptanib)
Macugen (pegaptanib) + Macugen (Pegaptanib) is a pre-clinical stage product being developed by Pfizer for Proliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00446381. Target conditions include Proliferative Diabetic Retinopathy, Diabetic Macular Edema.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00446381 | Pre-clinical | Completed |
Competing Products
20 competing products in Proliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| Epcoritamab | AbbVie | Phase 1 | 33 |
| Brolucizumab 6 mg | Novartis | Phase 3 | 77 |
| CANAKINUMAB (ILARIS®) | Novartis | Phase 1 | 33 |
| Lucentis | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Octreotide, 30 mg i.m. LAR formulation | Novartis | Phase 3 | 77 |
| Ranibizumab 0.5 mg | Novartis | Phase 2 | 52 |
| AUY922 | Novartis | Phase 2 | 52 |
| Lucentis | Roche | Pre-clinical | 23 |
| Macugen ® (pegaptanib sodium) | Pfizer | Approved | 84 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| 2-mg Intravitreous Aflibercept Injection | Regeneron Pharmaceuticals | Phase 2/3 | 64 |